Vie Ventures

vieventures.com

VCMatch tracks Vie Ventures as an investor focused on Biotech companies, Series B and Series C rounds, and United States markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Series B, Series C

Focus Areas

Biotech

Geography

United States

Investment Thesis

Vie Ventures positions itself as a hybrid, mission-aligned life sciences investor that explicitly bridges traditional venture capital and disease-focused philanthropy to accelerate development of therapeutics. The firm combines a “returns-oriented approach” with mission impact by investing alongside other VCs and strategic partners (primarily in Series B/C clinical-stage companies) and leveraging a network of disease philanthropy collaborators to make more informed, value-added investments that increase the probability of clinical and commercial success.

Is Vie Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Vie Ventures is most relevant for founders raising Series B and Series C rounds in Biotech, especially across United States.

Focus statement

Vie Ventures focuses on investing in therapeutic companies advancing novel treatments for autoimmune disease and other disorders of the immune system, primarily by participating in Series B and C-stage private biotech financings and partnering with disease-focused philanthropies and patient organizations.

Value Add

Explicitly positions itself as a bridge between venture capital and disease philanthropy (e.g., works with Crohn's & Colitis Foundation, Lupus Research Alliance, National Multiple Sclerosis Society, Scleroderma Research Foundation, Sjögren's Foundation).
Invests primarily in Series B and C-stage private biotech companies focused on autoimmune and immune-mediated diseases (clinical-stage focus noted repeatedly).
Operates structured collaboration mechanisms such as the Therapeutics Advisory Council (TAC) to create a “cross-disease, cross-sector framework” aligning philanthropy with market-driven innovation.
Leadership team with deep, complementary expertise in immunology, venture investing, biotech company building, and patient-focused philanthropy (founders from MPM, T1D Fund; Jeff Bluestone as immunology leader).
Aligned financial incentives and philanthropy: co-founders pledged a share of their own proceeds and established Vie Ventures Foundation to accelerate innovation in autoimmune and inflammatory diseases.
Emphasis on being a “value-added investment partner” through strategic collaborator networks and patient-expert engagement rather than sole capital provider.